Puig Ignasi, López-Góngora Sheila, Calvet Xavier, Villoria Albert, Baylina Mireia, Sanchez-Delgado Jordi, Suarez David, García-Hernando Victor, Gisbert Javier P
Digestive Diseases Unit, Althaia Xarxa Assistencial Universitaria de Manresa. Barcelona, Spain.
Internal Medicine Department, Corporació Sanitària Universitària Parc Taulí, Sabadell, Spain.
Therap Adv Gastroenterol. 2016 Jul;9(4):437-48. doi: 10.1177/1756283X15621229. Epub 2015 Dec 16.
Susceptibility-guided therapies (SGTs) have been proposed as preferable to empirical rescue treatments after two treatment failures. The aim of this study was to perform a systematic review and meta-analysis evaluating the effectiveness and efficacy of SGT as third-line therapy.
A systematic search was performed in multiple databases. Studies reporting cure rates of Helicobacter pylori with SGT in third-line therapy were selected. A qualitative analysis describing the current evidence and a pooled mean analysis summarizing the cure rates of SGT in third-line therapy was performed.
No randomized controlled trials or comparative studies were found. Four observational studies reported cure rates with SGT in third-line treatment, and three studies which mixed patients with second- and third-line treatment also reported cure rates with SGT. The majority of the studies included the patients when culture had been already obtained, and so the effectiveness of SGT and empirical therapy has never been compared. A pooled mean analysis including four observational studies (283 patients) showed intention-to-treat and per-protocol eradication rates with SGT of 72% (95% confidence interval 56-87%; I(2) : 92%) and 80% (95% confidence interval 71-90%; I(2) : 80%), respectively.
SGT may be an acceptable option as rescue treatment. However, cure rates are, at best, moderate and this approach has never been compared with a well-devised empirical therapy. The evidence in favor of SGT as rescue therapy is currently insufficient to recommend its use.
在两次治疗失败后,药敏指导治疗(SGT)被认为比经验性挽救治疗更可取。本研究的目的是进行一项系统评价和荟萃分析,以评估SGT作为三线治疗的有效性和疗效。
在多个数据库中进行系统检索。选择报告SGT在三线治疗中幽门螺杆菌治愈率的研究。进行了描述当前证据的定性分析和汇总SGT在三线治疗中治愈率的合并均值分析。
未找到随机对照试验或比较研究。四项观察性研究报告了SGT在三线治疗中的治愈率,三项将二线和三线治疗患者混合的研究也报告了SGT的治愈率。大多数研究纳入了已经获得培养结果的患者,因此从未比较过SGT和经验性治疗的有效性。一项纳入四项观察性研究(283例患者)的合并均值分析显示,SGT的意向性治疗和符合方案根除率分别为72%(95%置信区间56-87%;I²:92%)和80%(95%置信区间71-90%;I²:80%)。
SGT作为挽救治疗可能是一个可接受的选择。然而,治愈率充其量只是中等水平,并且这种方法从未与精心设计的经验性治疗进行过比较。支持SGT作为挽救治疗的证据目前不足以推荐其使用。